ライフサイエンスコーパス: Kaposi

1 Kaposi sarcoma (KS) can develop following organ transpla

2 Kaposi sarcoma (KS) gained public attention as an AIDS-d

3 Kaposi sarcoma (KS) had the highest IR (634.7 per 100 00

4 Kaposi sarcoma (KS) is a complication of KS-associated h

5 Kaposi sarcoma (KS) remains a frequent cancer in human i

6 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) is eti

7 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) subtyp

8 Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi

9 Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent

10 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpe

11 Kaposi sarcoma is a vascular tumor related to herpesviru

12 Kaposi sarcoma is caused by infection of Kaposi sarcoma-

13 Kaposi sarcoma is the most common cancer in human immuno

14 Kaposi sarcoma is the most common human herpesvirus 8 (H

15 Kaposi sarcoma occurred during the first year after tran

16 Kaposi sarcoma-associated herpesvirus (KSHV) is an emerg

17 Kaposi sarcoma-associated herpesvirus (KSHV) is necessar

18 Kaposi sarcoma-associated herpesvirus (KSHV), also known

19 Kaposi sarcoma-associated herpesvirus (KSHV), one of the

20 Kaposi sarcoma-associated herpesvirus/human herpesvirus

21 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

22 Kaposi's sarcoma (KS) as the most common AIDS-associated

23 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarco

24 Kaposi's sarcoma (KS) is a rare vascular tumor associate

25 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) infe

26 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is t

27 Kaposi's sarcoma associated herpesvirus (KSHV) establish

28 Kaposi's sarcoma is a highly angiogenic tumor that arise

29 Kaposi's sarcoma is a highly vascular tumor, which prefe

30 Kaposi's sarcoma is one of the most common malignancies

31 Kaposi's sarcoma-associated herpes virus (KSHV) is the c

32 Kaposi's sarcoma-associated herpes virus (KSHV) polyaden

33 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

34 Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

35 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

36 Kaposi's sarcoma-associated herpesvirus (KSHV) enters hu

37 Kaposi's sarcoma-associated herpesvirus (KSHV) has a cau

38 Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

39 Kaposi's sarcoma-associated herpesvirus (KSHV) has tropi

40 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

41 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

42 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

43 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

44 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

45 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

46 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

47 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

48 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

49 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

50 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

51 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

52 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

53 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

54 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

55 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

56 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

57 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

58 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

59 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

60 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

61 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

62 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

63 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

64 Kaposi's sarcoma-associated herpesvirus (KSHV) latency-a

65 Kaposi's sarcoma-associated herpesvirus (KSHV) maintains

66 Kaposi's sarcoma-associated herpesvirus (KSHV) transcrib

67 Kaposi's sarcoma-associated herpesvirus (KSHV) transcrip

68 Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

69 Kaposi's sarcoma-associated herpesvirus (KSHV)-induced a

70 Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

71 Kaposi's sarcoma-associated herpesvirus (KSHV; also call

72 Kaposi's sarcoma-associated herpesvirus is a leading cau

73 e infected with human herpesvirus 8 (HHV-8) (Kaposi's sarcoma [KS]-associated herpesvirus) and have a

74 V1) lineage consists of human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus (KSHV), and clos

75 egy of selectively isolating VLVs by using a Kaposi's sarcoma-associated herpesvirus (KSHV) mutant th

76 rt to block the interaction between vFLIP, a Kaposi's sarcoma herpesviral oncoprotein, and NEMO using

77 al interferon regulatory factor 1 (vIRF1), a Kaposi sarcoma herpesvirus protein, destabilizes p53 by

78 cell carcinoma of the skin were found after Kaposi sarcoma (685.68) and Merkel cell carcinoma (117.2

79 The responsible agent, Kaposi's sarcoma-associated herpesvirus (KSHV; HHV8), ex

80 ous conditions such as hepatitis C, but also Kaposi sarcoma, clustered significantly, suggesting tran

81 Although Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52 (al

82 ere more common in white OTRs (P < .001) and Kaposi sarcoma was more common in black OTRs (P < .001).

83 Co-infection with HIV-1 and Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

84 atently infected TIVE-LTC and PEL cells, and Kaposi's sarcoma skin lesion cells.

85 two B-cell lymphoproliferative diseases and Kaposi's sarcoma, an endothelial-cell-driven cancer.

86 n tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish p

87 ressed from the Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) human DNA tumor viru

88 Both Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are human

89 al carcinogens, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are two o

90 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) cause lif

91 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) utilize c

92 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), can caus

93 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), which ar

94 rcoma, epithelioid hemangioendothelioma, and Kaposi sarcoma are classified according to the line of d

95 an's disease, primary effusion lymphoma, and Kaposi's sarcoma.

96 elated malignancies, including lymphomas and Kaposi's sarcoma.

97 tors (e.g., herpes simplex virus nectin1 and Kaposi's sarcoma-associated herpesvirus EphA2), or assoc

98 ncluding primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

99 mutant with prototype foamy virus (PFV) and Kaposi's sarcoma herpesvirus (KSHV) tethering sequences

100 he gammaherpesviruses Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.

101 f the human pathogens Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus.

102 ciated polyomavirus, Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus, because GEMs ha

103 y focal assembly of RNA polymerase II around Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

104 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an on

105 gnancies except for specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

106 DNA tumor viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) are known

107 that are characteristic of HHV-8-associated Kaposi's sarcoma, PEL and multicentric Castleman's disea

108 nd angiogenic activities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

109 giogenic viral proteins, in HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

110 with HIV and advanced stage AIDS-associated Kaposi sarcoma attending 11 AIDS Clinical Trials Group s

111 its use in treating advanced AIDS-associated Kaposi sarcoma in resource-limited settings.

112 timal treatment regimens for AIDS-associated Kaposi sarcoma, a frequent contributor to morbidity and

113 -cell pathologies, including AIDS-associated Kaposi's sarcoma and multicentric Castleman's disease.

114 Both Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

115 emonstrate that RelA/NF-kappaB activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP

116 Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus (KSHV) infection and is thoug

117 virus-positive individuals and is caused by Kaposi sarcoma-associated herpesvirus (KSHV).

118 nown inflammation related diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

119 rcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus.

120 s KSHV-miR-K12-11 and MDV-miR-M4, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) and Marek

121 odgkin lymphoma associated with infection by Kaposi sarcoma-associated herpes virus (KSHV).

122 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative d

123 9, 95% CI 1.67-1.72), AIDS-defining cancers (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin ly

124 shown that, unlike glucose-addicted cancers, Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

125 nvasive and in situ squamous cell carcinoma, Kaposi sarcoma, and Merkel cell carcinoma.

126 (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS).

127 is an oncogenic gammaherpesvirus that causes Kaposi's sarcoma and other lymphoproliferative disorders

128 ow that HHV-8, a DNA tumor virus that causes Kaposi's sarcoma, infects three types of dendritic cells

129 Human herpesvirus 8, which causes Kaposi sarcoma, expresses the MARCH family ubiquitin lig

130 We compared Kaposi sarcoma (KS) risk in adults who started antiretro

131 likely to play a pivotal role in controlling Kaposi sarcoma (KS)-associated herpesvirus (KSHV) and pr

132 we present an innovative approach to culture Kaposi's sarcoma-associated herpesvirus (KSHV) infected

133 Detectable Kaposi's sarcoma-associated herpesvirus (KSHV) DNA in bl

134 metabolic complications, frequently develop Kaposi sarcoma.

135 infected patients who subsequently developed Kaposi sarcoma were included.

136 posttransplant period, one of whom developed Kaposi sarcoma.

137 DNA tumor viruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), and huma

138 We assessed whether elevated Kaposi's sarcoma-associated herpesvirus (KSHV) viral loa

139 is etiologically associated with endothelial Kaposi's sarcoma (KS) in immunocompromised individuals.

140 revealed 3 distinct HHV-8-related entities: Kaposi sarcoma, HHV-8-associated multicentric Castleman

141 without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.

142 decreased significantly across 1996-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma,

143 infection and KS.IMPORTANCE The ability for Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

144 erpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

145 d herpesvirus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in HIV

146 d herpesvirus (KSHV) is the causal agent for Kaposi's sarcoma (KS), the most common malignancy in peo

147 ren with Kaposi sarcoma who met criteria for Kaposi sarcoma herpesvirus (KSHV) inflammatory cytokine

148 Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence i

149 virus type 1 (HIV-1) infection and risk for Kaposi sarcoma, but behaviors associated with HHV-8 tran

150 A-binding domains (DBDs), LANA homologs from Kaposi sarcoma-associated herpesvirus (KSHV) and MHV68 e

151 Using the dimeric protease (Pr) from Kaposi's sarcoma-associated herpesvirus (KSHV) as a mode

152 -like inhibitory protein (FLIP) protein from Kaposi sarcoma-associated herpesvirus activates the NF-k

153 iruses, including the human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), and the

154 omolog, the oncogenic human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus/human herpesviru

155 The oncogenic gammaherpesvirus Kaposi sarcoma-associated herpesvirus (KSHV) is globally

156 ed with the closely related gammaherpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) and the m

157 The human gammaherpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), is tight

158 the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targe

159 16) recognizes nuclear episomal herpesvirus (Kaposi's sarcoma-associated herpesvirus [KSHV], Epstein-

160 DSBs) in DNA, although detail concerning how Kaposi's sarcoma-associated herpesvirus (KSHV) modulates

161 luding human Epstein-Barr virus (EBV), human Kaposi's sarcoma-associated herpesvirus (KSHV), and muri

162 n KSHV-infected spindle tumor cells in human Kaposi sarcoma lesions.

163 of vGPCR-induced lesions that resemble human Kaposi's sarcoma.

164 Sequence comparisons to human Kaposi's sarcoma-associated herpesvirus (KSHV) miRNAs re

165 ting their premature accumulation.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc

166 g the intracellular redox balance.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

167 d transmission in the oral cavity.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

168 ive stages of the KSHV life cycle.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes AI

169 l that enhance antiviral defenses.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is causal

170 inhibiting viral gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is a path

171 ects in KSHV late gene expression.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

172 tic targets to control KS lesions.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) manipulat

173 ion that is transferable to MHV68.IMPORTANCE Kaposi sarcoma-associated herpesvirus (KSHV) and murine

174 predominantly canonical in nature.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

175 on of the STAT3 signaling pathway.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

176 s to block KSHV virion production.IMPORTANCE Kaposi's sarcoma (KS)-associated herpesvirus is the caus

177 to recognize late gene promoters.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV; human her

178 In Kaposi sarcoma tumors, SOX18 and PROX1 expression correl

179 In Kaposi's sarcoma-associated herpesvirus (KSHV), these vT

180 8 as a potential novel therapeutic avenue in Kaposi sarcoma.

181 of arachidonic acid pathways of the host in Kaposi's sarcoma-associated herpesvirus (KSHV) biology h

182 t HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at we

183 vironment supporting persistent infection in Kaposi sarcoma tumors.

184 by viral endoribonucleases, including SOX in Kaposi's sarcoma-associated herpesvirus (KSHV), muSOX in

185 The vTAs in Kaposi's sarcoma-associated herpesvirus (KSHV) are ORF18

186 s associated with several cancers, including Kaposi's sarcoma (KS).

187 egument proteins of herpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), play key

188 of immunocompromised individuals, including Kaposi's sarcoma (KS).

189 virus (KSHV)-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

190 several AIDS-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

191 n adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evo

192 veloping germinal center B cells, can induce Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

193 ved that a small number of latently infected Kaposi sarcoma tumor cells undergo spontaneous lytic rea

194 ted with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus.

195 nflammatory activities observed in MCD-like "Kaposi's sarcoma-associated herpesvirus-induced cytokine

196 Castleman's disease, as well as its namesake Kaposi's sarcoma.

197 pesvirus 8 (HHV-8) is the causative agent of Kaposi sarcoma (KS) and multicentric Castleman disease (

198 herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS), one of the leading cancers in human

199 gen and is the causative infectious agent of Kaposi sarcoma and two malignancies of B cell origin.

200 KSHV is the causative agent of Kaposi's sarcoma (KS) and other AIDS-related malignancie

201 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

202 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), a vascular tumor frequently found

203 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), an AIDS-defining cancer in HIV-1-

204 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), an AIDS-defining cancer with abno

205 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma (KS), to establish and maintain latency

206 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS).

207 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma and is associated with two B cell malig

208 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma and other B-cell cancers and remains a

209 rpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma and primary effusion lymphoma (PEL).

210 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, and a constitutively active viral G pr

211 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma, encodes 25 mature viral miRNAs.

212 rs.IMPORTANCE KSHV is the etiologic agent of Kaposi's sarcoma, the most common tumor of AIDS patients

213 Assembly of Kaposi's sarcoma-associated herpesvirus (KSHV) begins at

214 The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV

215 Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) rel

216 i sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

217 ncy is an integral part of the life cycle of Kaposi's sarcoma-associated herpesvirus (KSHV), an etiol

218 s tightly associated with the development of Kaposi's sarcoma and multicentric Castleman's disease, a

219 eta3 in KSHV pathogenesis and development of Kaposi's sarcoma.

220 Ca-SP also inhibited entry of Kaposi sarcoma-associated herpesvirus/human herpes virus

221 s etiologically associated with all forms of Kaposi's sarcoma worldwide.

222 n by HIV-1 promotes the aggressive growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

223 Kaposi sarcoma is caused by infection of Kaposi sarcoma-associated herpesvirus (KSHV) and is char

224 latency-associated nuclear antigen (LANA) of Kaposi sarcoma herpesvirus (KSHV) is mainly localized an

225 IFI16 knockdown disrupted the latency of Kaposi's sarcoma associated herpesvirus (KSHV) and induc

226 Molecular mechanisms of Kaposi's sarcoma-associated herpesvirus (KSHV) reactivat

227 We report that ORF10 of Kaposi's sarcoma-associated herpesvirus (KSHV), a nuclea

228 encoded by open reading frame 36 (ORF36) of Kaposi's sarcoma-associated herpesvirus (KSHV) enhances

229 for lifelong persistence and pathogenesis of Kaposi's sarcoma-associated herpesvirus (KSHV).

230 ed for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesviru

231 atabase (19 077 patients), the prevalence of Kaposi sarcoma was 0.18% and 0.46%, respectively, in tra

232 High prevalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

233 The K1 gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) is encode

234 al role in the initiation and progression of Kaposi's sarcoma tumors.

235 firmed in the TR and viral Bcl-2 promoter of Kaposi sarcoma-associated herpesvirus (KSHV).

236 The K15P membrane protein of Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

237 lytic phases.IMPORTANCE The K15P protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is though

238 Reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) from late

239 ing TRIM43, that control the reactivation of Kaposi's sarcoma-associated herpesvirus.

240 Specific regions of Kaposi's sarcoma-associated herpesvirus (KSHV) latent ep

241 Latent DNA replication of Kaposi's sarcoma-associated herpesvirus (KSHV) initiates

242 The lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV) requires

243 However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endem

244 ents might increase the risk and severity of Kaposi sarcoma.

245 tients at the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic infections (GHESKIO)

246 is the most effective therapeutic target of Kaposi sarcoma, which is caused by infection with the Ka

247 iral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against

248 Effects of Ca-SP on Kaposi sarcoma-associated herpesvirus/human herpes virus

249 Oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

250 Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a high

251 ng protein (vFLIP), encoded by the oncogenic Kaposi sarcoma-associated herpes virus (KSHV), constitut

252 Here, we addressed whether the oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) deregulat

253 nfected with either human cytomegalovirus or Kaposi's sarcoma-associated herpesvirus.

254 ce of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin.

255 During the latent phase, Kaposi's sarcoma-associated herpes virus (KSHV) maintain

256 nd was treated with the usual posttransplant Kaposi sarcoma management protocol.

257 Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by

258 Moreover, a recombinant Kaposi's sarcoma-associated herpesvirus (KSHV) expressin

259 SHV) is the cause of aggressive AIDS-related Kaposi's sarcoma (AIDS-KS) characterized by abnormal ang

260 ecimens of 11 HIV-related, 7 non-HIV-related Kaposi sarcoma (KS), and 7 normal skin tissues (NSTs) of

261 nprecedented mechanism of viral replication: Kaposi's sarcoma-associated herpesvirus (KSHV) stably cl

262 at the constitutive AMPK activity restricted Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

263 script C19ORF66 and showed that it restricts Kaposi's sarcoma-associated herpesvirus (KSHV) infection

264 Similarly, Kaposi's sarcoma-associated herpesvirus also did not sti

265 In our study, Kaposi sarcoma in transplanted patients with HIV did not

266 e in lymphatic endothelial cells, supporting Kaposi sarcoma tumorigenesis and representing attractive

267 r, Ago2 and DCP1A, in PB formation, and that Kaposi's sarcoma-associated herpesvirus (KSHV) lytic inf

268 ies.IMPORTANCE We have previously shown that Kaposi's sarcoma-associated herpesvirus (KSHV)-transform

269 Recent studies have suggested that Kaposi sarcoma (KS) rates might be increasing in some ra

270 The Kaposi's sarcoma-associated herpesvirus (KSHV) alkaline

271 The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded l

272 The Kaposi's sarcoma-associated herpesvirus homologue, ORF61

273 e found that most transcripts encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome un

274 ing an m(6)A-modified hairpin present in the Kaposi's sarcoma associated herpesvirus (KSHV) ORF50 RNA

275 on factors which play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) latent an

276 e factors (HIFs) play important roles in the Kaposi's sarcoma-associated herpesvirus (KSHV) life cycl

277 ous transcription across the entirety of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome an

278 ncy-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus (KSHV) performs

279 Here, we show that the Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded L

280 s, the cofactor activity (CFA), by using the Kaposi's sarcoma-associated herpesvirus RCA homolog Kapo

281 rcoma, which is caused by infection with the Kaposi sarcoma-associated herpesvirus (KSHV).

282 The median time from HIV infection to Kaposi sarcoma was 20 years.

283 ted herpesvirus (KSHV) is causally linked to Kaposi's sarcoma and several lymphoproliferative disease

284 d mesenchymal stem cells, which give rise to Kaposi sarcoma tumors.

285 ssociated with the endothelial-derived tumor Kaposi sarcoma.

286 esvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicent

287 The DNA virus Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

288 In 21 cutaneous and/or visceral Kaposi's sarcoma cases, occurring in patients living wit

289 d levels of viral lytic gene expression when Kaposi's sarcoma-associated herpesvirus (KSHV) infected

290 This study defines the mechanism by which Kaposi's sarcoma could be maintained by virus constantly

291 ion lymphoma (PEL) cases are associated with Kaposi sarcoma-associated herpesvirus (KSHV).

292 ymphomas (PELs) are causally associated with Kaposi's sarcoma-associated herpesvirus (KSHV) and 86% o

293 L) is a lymphogenic disorder associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection

294 ciency virus-infected Malawian children with Kaposi sarcoma who met criteria for Kaposi sarcoma herpe

295 ected cells.IMPORTANCE B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) harbor mu

296 rophoretic response of B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) were inve

297 lular reservoir in individuals infected with Kaposi's sarcoma-associated herpesvirus (KSHV), and the

298 EL), which is a viral lymphoma infected with Kaposi's sarcoma-associated herpesvirus (KSHV).

299 rtant role in early childhood infection with Kaposi sarcoma-associated herpesvirus (KSHV), the matern

300 ual men were over-represented among men with Kaposi's sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal